TSH promotes hepatic triglyceride accumulation and hypercholesterolemia by lowering the activity of hepatic lipoprotein lipase, activating the PPAR pathway, the sterol regulatory element-binding transcription factor 1c (SREBP1), and decreasing the phosphorylation of 3-hydroxy3-methylglutaryl coenzyme A reductase [18, 19]. The gene discussed is SREBF1; the disease is familial hypercholesterolemia.